I found 106 US Biotechnology Companies classified in the Health Care Sector at Yahoo's superb Finance website with current Total Market Capitalizations of at least $100 mil each and which also had their common stocks trading on each of the following three dates:
- On December 31, 2007 during President Bush's second term
- On March 6, 2009, very early in President Obama's first term, which was their lowest point due to the spillover effects resulting from the 2008 financial meltdown, and
- also on the most recent date February 4, 2014.
The historical common stock prices of these companies were obtained from the following two excellent internet resources.... Google Finance and MarketWatch Big Charts.
Included in these 106 largest US Biotechnology Companies shown later below were two which encountered Reverse Mergers. One of these two is Clarence, NY-based 22nd Century Group.....a plant biotechnology company focusing on smoking cessation.
22nd Century had its common stock trading at a meager $.0018 on March 6, 2009 before its Reverse Merger occurred. Its common stock is now selling on the most recent date February 4, 2014 for $2.37, an increase of an astronomical 131,567% in less than five years.
When the two companies having Reverse Mergers are included, these 106 US Biotechs had their average common stock prices increase by a spectacular 1,796% since March 6, 2009.
Because of the astronomical percentage increase in the stock market price of 22nd Century Group, let me show what has happened to the stock prices of the other 104 US Biotechs.
These 104 US Biotechs had their average stock prices drop by a huge 43% from December 31, 2007 during President Bush's second Presidential term, to March 6, 2009, very early in President Obama's first term, which was the very lowest point for the overall stock market due to the spillover effects resulting from the disastrous 2008 Financial Meltdown.
But in the slightly less than five years since March 6, 2009, the average stock prices of these same 104 US Biotechs have increased by a very impressive 566% through February 4, 2014.
The exceptionally well run Jazz Pharmaceuticals is legally headquartered in the Ireland foreign tax haven but has substantial operations in California's Silicon Valley. Its spectacularly off-the-charts 23,655% stock price growth is the main driver of the exceptional 566% average stock market increase for all 104 US Biotechs since March 6, 2009.
In addition to Jazz Pharmaceuticals, there were 9 other "Ten Baggers Plus".....stock market price growth of at least 10 times in the slightly less than five years since March 6, 2009.
There were four "Twenty Baggers Plus".....Wilmington, DE-based Incyte (up 2,841%), San Diego, CA-based ACADIA Pharmaceuticals (up 2.739%) and Tarreytown, NY-based Regeneron Pharmaceuticals (up 2,167%).....in addition to Palo Alto, CA-based Jazz Pharmaceuticals.
Clearly, the investors in and employees of a clear majority of these 106 US largest US Biotechnology Companies must be extremely pleased with the impact of actions taken by both the Obama Administration and the US Fed to successfully rescue the US economy from its extremely weakened state.
Also, a clear majority of these US Biotechnology Companies have flat out thrived from the Affordable Care Act. Wise investors have moved up their common stock market prices smartly in anticipation of many more US citizens being covered by insurance and by Medicaid Expansion.
US Biotechnology Companies are overwhelmingly based in Blue States. Of these 106 largest US Biotechs, more than half of them are headquartered in two very progressive US States.....35 in California and 20 in Massachusetts. Only 4 of the 106 largest US Biotechs are headquartered in US States that didn't vote for Barack Obama in 2008. And only 8 of the 106 are based in US States that didn't vote for Barack Obama in 2012.
The common stock market prices of US Biotechnology Companies are highly volatile. Of the 106 largest US Biotechs, 23 of them have had reverse stock splits since December 31, 2007. The chart below properly restates the stock market prices on both December 31, 2007 and March 6, 2009 for the impact of these reverse stock splits.
Below here are the stock market prices of each of these 106 US largest US Biotechnology Companies on February 4, 2014, on March 6, 2009, and on December 31, 2007:
| Market | Market | ||||||
| Price | Price | ||||||
| % | % | ||||||
| Change | Change | ||||||
| Market | Market | Market | 3-6-09 | 12-31-07 | |||
| Price | Price | Price | to | to | |||
| Biotechnology Company | HQs | 2-4-14 | 3-6-09 | 12-31-07 | 2-4-14 | 3-6-09 | |
| Jazz Pharmaceuticals | Palo Alto | CA | 147.280 | 0.620 | 14.700 | 23655% | -96% |
| Incyte | Wilmington | DE | 62.930 | 2.140 | 10.050 | 2841% | -79% |
| ACADIA Pharmaceuticals | San Diego | CA | 22.710 | 0.800 | 11.070 | 2739% | -93% |
| Regeneron Pharmaceuticals | Tarreytown | NY | 287.230 | 12.670 | 24.150 | 2167% | -48% |
| Exact Sciences | Madison | WI | 12.290 | 0.771 | 3.220 | 1494% | -76% |
| Vanda Pharmaceuticals | Washington | DC | 11.410 | 0.803 | 6.880 | 1322% | -88% |
| Cambrex | East Rutherford | NJ | 19.910 | 1.500 | 8.380 | 1227% | -82% |
| Synageva BioPharma | Lexington | MA | 87.660 | 6.700 | 34.900 | 1208% | -81% |
| Questcor Pharmaceuticals | Anaheim | CA | 63.710 | 5.020 | 5.770 | 1169% | -13% |
| ViroPharma | Exton | PA | 49.960 | 4.080 | 7.940 | 1125% | -49% |
| Medivation | San Francisco | CA | 76.580 | 7.640 | 7.200 | 902% | 6% |
| Alexion Phramaceuticals | Cheshire | CT | 156.210 | 16.140 | 18.758 | 868% | -14% |
| Novavax | Rockville | MD | 5.390 | 0.560 | 3.330 | 863% | -83% |
| Anika Therapeutics | Bedford | MA | 31.360 | 3.550 | 14.550 | 783% | -76% |
| Cerus | Concord | CA | 5.960 | 0.710 | 6.510 | 739% | -89% |
| NPS Pharmaceuticals | Bedminster | NJ | 34.030 | 4.060 | 3.830 | 738% | 6% |
| BioCryst Pharmaceuticals | Durham | NC | 9.490 | 1.190 | 6.180 | 697% | -81% |
| BioTime | Alameda | CA | 3.390 | 0.480 | 0.480 | 606% | 0% |
| Biogen Idec | Cambridge | MA | 308.180 | 44.230 | 56.920 | 597% | -22% |
| Inovio Pharmaceuticals | Blue Bell | PA | 2.500 | 0.370 | 0.920 | 576% | -60% |
| BioMarin Pharmaceutical | San Rafael | CA | 68.140 | 10.220 | 35.400 | 567% | -71% |
| Sangamo Biosciences | Richmond | CA | 19.430 | 2.990 | 13.021 | 550% | -77% |
| Sarepta Therapeutics | Cambridge | MA | 22.960 | 3.780 | 8.460 | 507% | -55% |
| Seattle Genetics | Bothell | WA | 43.900 | 7.230 | 11.400 | 507% | -37% |
| Athersys | Cleveland | OH | 3.480 | 0.580 | 4.910 | 500% | -88% |
| Ariad Pharmaceuticals | Cambridge | MA | 7.000 | 1.200 | 4.250 | 483% | -72% |
| ZIOPHARM Oncology | Boston | MA | 4.060 | 0.700 | 3.540 | 480% | -80% |
| IGI Laboratories | Buena | NJ | 3.240 | 0.570 | 1.410 | 468% | -60% |
| Spectrum Pharmaceuticals | Henderson | NV | 8.050 | 1.430 | 2.720 | 463% | -47% |
| Alnylam Pharmaceuticals | Cambridge | MA | 77.82 | 15.790 | 29.08 | 393% | -46% |
| Immunomedics | Morris Plains | NJ | 4.680 | 0.950 | 2.320 | 393% | -59% |
| Illumina | San Diego | CA | 151.590 | 31.980 | 29.630 | 374% | 8% |
| Celldex Therapeutics | Needham | MA | 25.260 | 5.350 | 6.000 | 372% | -11% |
| Threshold Pharmaceuticals | South San Francisco | CA | 4.540 | 1.080 | 3.180 | 320% | -66% |
| Repligen | Waltham | MA | 14.430 | 3.730 | 6.550 | 287% | -43% |
| Dyax | Burlington | MA | 8.300 | 2.170 | 3.660 | 282% | -41% |
| Gilead Sciences | Foster City | CA | 82.02 | 22.005 | 23.005 | 273% | -4% |
| Neuralstem | Rockville | MD | 3.180 | 0.860 | 3.730 | 270% | -77% |
| Celgene | Summit | NJ | 151.510 | 41.160 | 46.210 | 268% | -11% |
| Ligand Pharmaceuticals | La Jolla | CA | 59.330 | 16.560 | 28.980 | 258% | -43% |
| Arrowhead Research | Pasadena | CA | 14.600 | 4.300 | 37.800 | 240% | -89% |
| CytRx | Los Angeles | CA | 6.570 | 1.960 | 19.880 | 235% | -90% |
| ImmunoGen | Waltham | MA | 15.050 | 4.910 | 4.150 | 207% | 18% |
| Corcept Therapeutics | Menlo Park | CA | 3.060 | 1.000 | 3.090 | 206% | -68% |
| Nektar Therapeutics | San Francisco | CA | 12.710 | 4.210 | 6.710 | 202% | -37% |
| Chelsea Therapeutics | Charlotte | NC | 4.510 | 1.500 | 7.350 | 201% | -80% |
| Theravance | South San Francisco | CA | 36.150 | 12.150 | 19.500 | 198% | -38% |
| Cornerstone Therapeutics | Cary | NC | 9.490 | 3.206 | 12.700 | 196% | -75% |
| Halozyme Therapeutics | San Diego | CA | 13.780 | 4.660 | 7.110 | 196% | -34% |
| Vertex Pharmaceuticals | Cambridge | MA | 79.150 | 27.770 | 23.230 | 185% | 20% |
| Sunesis Pharmaceuticals | South San Francisco | CA | 4.160 | 1.500 | 11.940 | 177% | -87% |
| OncoGenex Pharmaceuticals | Bothell | WA | 10.640 | 3.900 | 7.920 | 173% | -51% |
| BioDelivery Sciences | Raleigh | NC | 7.730 | 2.920 | 2.930 | 165% | 0% |
| Idenix Pharmaceuticals | Cambridge | MA | 6.730 | 2.670 | 2.700 | 152% | -1% |
| Amgen | Thousand Oaks | CA | 115.780 | 46.380 | 46.440 | 150% | 0% |
| Oncothyreon | Seattle | WA | 2.170 | 0.900 | 2.230 | 141% | -60% |
| MannKind | Valencia | CA | 5.160 | 2.170 | 7.960 | 138% | -73% |
| Applied DNA Sciences | Stony Brook | NY | 0.154 | 0.065 | 0.100 | 137% | -35% |
| TrovaGene | San Diego | CA | 5.300 | 2.280 | 4.020 | 132% | -43% |
| Curis | Lexington | MA | 2.730 | 1.180 | 0.980 | 131% | 20% |
| VIVUS | Mountain View | CA | 6.980 | 3.100 | 5.180 | 125% | -40% |
| Synta Pharmaceuticals | Lexington | MA | 5.250 | 2.380 | 6.700 | 121% | -64% |
| Charles River Laboratories | Wilmington | MA | 55.370 | 25.120 | 65.800 | 120% | -62% |
| Insmed | Monmouth Junction | NJ | 19.160 | 8.700 | 8.300 | 120% | 5% |
| Achillion Pharmaceuticals | New Haven | CT | 3.200 | 1.480 | 4.990 | 116% | -70% |
| Rexahn Pharmaceuticals | Rockville | MD | 1.080 | 0.510 | 2.250 | 112% | -77% |
| Geron | Menlo Park | CA | 7.350 | 3.870 | 5.680 | 90% | -32% |
| Cadence Pharmaceuticals | San Diego | CA | 10.720 | 5.830 | 14.860 | 84% | -61% |
| Techne | Minneapolis | MN | 85.08 | 46.98 | 66.05 | 81% | -29% |
| Array BioPharma | Boulder | CO | 4.700 | 2.600 | 8.420 | 81% | -69% |
| Cell Therapeutics | Seattle | WA | 3.06 | 1.698 | 564.00 | 80% | -100% |
| Targacept | Winston-Salem | NC | 4.310 | 2.440 | 8.260 | 77% | -70% |
| Lexicon Pharmaceuticals | Woodlands | TX | 1.750 | 1.020 | 3.030 | 72% | -66% |
| Agenus | Lexington | MA | 2.900 | 1.800 | 12.240 | 61% | -85% |
| Neostem | New York | NY | 7.000 | 4.500 | 13.400 | 56% | -66% |
| Infinity Pharmaceuticals | Cambridge | MA | 12.360 | 8.000 | 9.550 | 55% | -16% |
| Exelixis | South San Francisco | CA | 6.620 | 4.340 | 8.630 | 53% | -50% |
| Arena Pharmaceuticals | San Diego | CA | 6.070 | 4.060 | 7.830 | 50% | -48% |
| PDL BioPharma | Incline Village | NV | 8.380 | 6.270 | 12.459 | 34% | -50% |
| Albany Molecular Research | Albany | NY | 10.500 | 7.940 | 14.380 | 32% | -45% |
| Acorda Therapeutics | Ardsley | NY | 28.770 | 23.440 | 21.960 | 23% | 7% |
| Emergent BioSolutions | Rockville | MD | 23.810 | 19.910 | 5.060 | 20% | 293% |
| BioSpecifics Technologies | Lynbrook | NY | 22.200 | 19.000 | 10.000 | 17% | 90% |
| Cytori Therapeutics | San Diego | CA | 2.570 | 2.310 | 6.050 | 11% | -62% |
| Peregrine Pharmaceuticals | Tustin | CA | 1.750 | 1.600 | 2.220 | 9% | -28% |
| Pain Therapeutics | Austin | TX | 3.920 | 3.840 | 10.600 | 2% | -64% |
| Dendreon | Seattle | WA | 2.650 | 2.610 | 6.220 | 2% | -58% |
| Intermune | Brisbane | CA | 12.480 | 13.630 | 13.330 | -8% | 2% |
| Vical | San Diego | CA | 1.250 | 1.430 | 4.250 | -13% | -66% |
| Osiris Therapeutics | Columbia | MD | 15.510 | 18.010 | 12.020 | -14% | 50% |
| XOMA | Berkeley | CA | 7.350 | 8.550 | 50.850 | -14% | -83% |
| Progenics Pharmaceuticals | Tarreytown | NY | 4.830 | 5.750 | 18.070 | -16% | -68% |
| Advanced Cell Technology | Marlborough | MA | 0.090 | 0.110 | 0.165 | -18% | -33% |
| Idera Pharmaceuticals | Cambridge | MA | 4.200 | 5.160 | 13.100 | -19% | -61% |
| ArQule | Woburn | MA | 2.220 | 3.000 | 5.800 | -26% | -48% |
| Repros Therapeutics | Woodlands | TX | 16.000 | 24.440 | 37.280 | -35% | -34% |
| Oragenics | Tampa | FL | 3.420 | 5.400 | 8.400 | -37% | -36% |
| Cytokinetics | South San Francisco | CA | 7.090 | 12.360 | 28.380 | -43% | -56% |
| ANI Pharmaceutics | Baudette | MN | 20.570 | 46.440 | 136.080 | -56% | -66% |
| Amicus Therapeutics | Cranbury | NJ | 2.630 | 7.260 | 10.750 | -64% | -32% |
| Xenoport | Santa Clara | CA | 5.850 | 18.090 | 55.880 | -68% | -68% |
| GTX Inc | Memphis | TN | 1.690 | 8.290 | 14.350 | -80% | -42% |
| Sequenom | San Diego | CA | 2.170 | 13.150 | 9.550 | -83% | 38% |
| Discovery Laboratories | Warrington | PA | 2.140 | 15.900 | 32.250 | -87% | -51% |
| Average % Change all 104 Before Reverse Mergers | 566% | -43% | |||||
| Reverse Mergers | |||||||
| 22nd Century Group | Clarence | NY | 2.370 | 0.002 | 0.072 | 131567% | -97% |
| TG Therapeutics | New York | NY | 5.810 | 112.500 | 281.500 | -95% | -60% |
| Average % Change all 106 Including Reverse Mergers | 1796% | ||||||
But it's not just the above 106 US Biotechs which are doing just great.
There are another 52 US Biotechs whose common stocks have first started trading in the most recent 3 years and which also now have Market Capitalizations of at least $100 mil each. Medical research hotbeds Cambridge, MA and San Diego, CA both headquarter 8 each of these 52. In total, 20 of the 52 were California based.
The below chart shows the market prices on the most recent date February 4, 2014 and also on the close of the first trading date of the 52 additional US Biotech companies with current Total Market Capitalizations of at least $100 mil each and whose common stocks have first started trading in the most recent 3 years:
| Closing | ||||||||
| Month | Price | |||||||
| Of | On | |||||||
| Market | First | First | ||||||
| Price | Trading | Trading | % | |||||
| Biotechnology Company | HQs | 2/4/2014 | Date | Date | Change | |||
| Actinium Pharmaceuticals | New York | NY | 5.65 | Jun 2011 | 0.11 | 5036% | ||
| Ignyta | San Diego | CA | 20.00 | Dec 2013 | 1.00 | 1900% | ||
| Northwest Biotherapeutics | Bethesda | MD | 5.09 | Jul 2012 | 0.32 | 1491% | ||
| Puma Biotechnology | Los Angeles | CA | 115.16 | Jun-12 | 12.50 | 821% | ||
| INSYS Therapeutics | Phoenix | AZ | 56.13 | May-13 | 9.50 | 491% | ||
| NewLink Genetics | Ames | IA | 36.99 | Nov-11 | 7.08 | 422% | ||
| Clovis Oncology | Boulder | CO | 63.16 | Nov-11 | 12.56 | 403% | ||
| Anacor Pharmaceuticals | Palo Alto | CA | 17.13 | Feb 2013 | 3.66 | 368% | ||
| Ocera Therapeutics | San Diego | CA | 13.09 | Apr 2011 | 4.00 | 227% | ||
| Receptos | San Diego | CA | 42.00 | May-13 | 14.00 | 200% | ||
| Hyperion Therapeutics | Brisbane | CA | 27.58 | Jul 2012 | 10.11 | 173% | ||
| Galena Biopharma | Lake Oswego | OR | 4.24 | Dec 2012 | 1.57 | 170% | ||
| Relypsa | Redwood City | CA | 32.37 | Nov-13 | 12.07 | 168% | ||
| Aratana Therapeutics | Kansas City | KS | 20.68 | Jun 2013 | 8.26 | 150% | ||
| Mirati Therapeutics | San Diego | CA | 20.18 | Aug 2013 | 9.05 | 123% | ||
| NanoString Technologies | Seattle | WA | 17.94 | Jun 2013 | 8.06 | 123% | ||
| Acceleron Pharma | Cambridge | MA | 44.48 | Sep-13 | 19.99 | 123% | ||
| Tesaro | Waltham | MA | 29.24 | Jun-12 | 13.69 | 114% | ||
| Regulus Therapeutics | San Diego | CA | 8.63 | Oct 2012 | 4.20 | 105% | ||
| Enanta Pharmaceuticals | Watertown | MA | 39.03 | Apr 2013 | 19.93 | 96% | ||
| Stemline Therapeutics | New York | NY | 23.49 | Jan 2013 | 12.20 | 93% | ||
| Cempra | Chapel Hill | NC | 11.66 | Feb 2012 | 6.06 | 92% | ||
| Portola Pharmaceuticals | South San Fran | CA | 25.05 | May-13 | 15.15 | 65% | ||
| Cellular Dynamics | Madison | WI | 15.25 | Jul 2013 | 9.50 | 61% | ||
| MacroGenics | Rockville | MD | 36.42 | Oct-13 | 24.99 | 46% | ||
| Endocyte | West Lafayette | IN | 11.26 | Feb 2011 | 7.73 | 46% | ||
| Ambit Biosciences | San Diego | CA | 10.40 | May 2013 | 7.39 | 41% | ||
| PTC Theraeutics | South Plainfield | NJ | 23.00 | Jun 2013 | 16.49 | 39% | ||
| Kindred Biosciences | Burlingame | CA | 16.52 | Dec 2013 | 11.95 | 38% | ||
| Epizyme | Cambridge | MA | 30.00 | May-13 | 22.99 | 30% | ||
| Intrexon | Germantown | MD | 31.31 | Aug-13 | 24.73 | 27% | ||
| TetraLogic Pharmaceuticals | Malvern | PA | 8.35 | Dec 2013 | 7.00 | 19% | ||
| Biota Pharmaceuticals | Alpharetta | GA | 4.90 | Nov 2012 | 4.12 | 19% | ||
| Durata Therapeutics | Chicago | IL | 10.58 | Jul 2012 | 9.04 | 17% | ||
| Ophthotech | New York | NY | 30.51 | Sep-13 | 26.30 | 16% | ||
| OncoMed Pharmaceuticals | Redwood City | CA | 30.35 | Jul-13 | 27.18 | 12% | ||
| Verastem | Cambridge | MA | 12.29 | Jan 2012 | 11.09 | 11% | ||
| Veracyte | South San Francisco | CA | 14.46 | Oct 2013 | 13.25 | 9% | ||
| Xencor | Monrovia | CA | 8.96 | Dec 2012 | 8.34 | 7% | ||
| Chimerix | Durham | NC | 19.30 | Apr 2013 | 18.79 | 3% | ||
| Conatus Pharmaceuticals | San Diego | CA | 9.51 | Jul 2013 | 9.50 | 0% | ||
| Esperion Therapeutics | Plymouth | MI | 14.44 | Jun 2013 | 14.50 | 0% | ||
| Five Prime Therapeutics | South San Francisco | CA | 12.83 | Sep 2013 | 13.08 | -2% | ||
| Fate Therapeutics | San Diego | CA | 6.17 | Oct 2013 | 6.62 | -7% | ||
| BIND Therapeutics | Cambridge | MA | 12.56 | Sep 2013 | 14.09 | -11% | ||
| Agios Pharmaceuticals | Cambridge | MA | 27.80 | Jul-13 | 31.28 | -11% | ||
| Ultragenyx Pharmaceutical | Novato | CA | 36.26 | Jan 2014 | 42.25 | -14% | ||
| Merrimack Pharmaceuticals | Cambridge | MA | 5.02 | Mar 2012 | 6.04 | -17% | ||
| OvaScience | Cambridge | MA | 9.63 | Apr 2013 | 11.70 | -18% | ||
| bluebird bio | Cambridge | MA | 20.79 | Jun 2013 | 26.91 | -23% | ||
| Onconova Therapeutics | Newtown | PA | 14.54 | Jun 2013 | 19.88 | -27% | ||
| ChemoCentryx | Mountain View | CA | 6.35 | Feb 2012 | 11.00 | -42% | ||
| Average % Increase all 52 | 254% |
The average stock market price increase for the above 52 US Biotechs first trading in the most recent three years is a very robust 254%, and this is for a very short period of time.
These recent IPOs in the past three years with a current Market Capitalization of at least $100 mil each have grown like weeds.....in fact, one of them INSYS Therapeutics literally. Of the above 52 IPOs, 5 of them went public in 2011, 13 in 2012 and 33 in 2013, and 1 in January 2014.
Clearly, US Biotech companies have done extremely well during the Obama Administration, and it appears that they have really picked up steam in 2013. This is a very good development, not just for the better US health outcomes for the country's citizens, but also for the US economy.
